HOME >> BIOLOGY >> NEWS
Latest data shows MabThera provides significant, sustained relief from symptoms of RA

Barcelona, Spain. New data presented at the EULAR meeting (European League Against Rheumatism) demonstrate that MabThera's (rituximab) effectiveness in relieving patients of the distressing symptoms of rheumatoid arthritis (RA) is sustained or further improved with subsequent courses of treatment, as is the number of patients achieving remission1. Importantly, the safety profile of MabThera remained unchanged in patients who had received as many as seven courses of treatment at 6-12 month intervals.

Commenting on the findings, Professor Keystone, Rheumatology Department at the University of Toronto, Canada, said: "As physicians gain experience with MabThera and the long-term efficacy and safety data are collected, we are able to make treatment decisions with confidence for the ultimate benefit of our patients."

Results following subsequent courses of therapy

A total of 1053 RA patients was treated with MabThera with almost 70% of patients followed up for more than two years and 11% for more than three years. The study was conducted in patients who had an inadequate response to treatment with either tumour necrosis factor (TNF) inhibitors or disease-modifying anti-rheumatic drugs (DMARDs), both of which are commonly used classes of RA drugs. All study patients received multiple courses of MabThera (2 x1000mg infusion, 2 weeks apart) based on disease activity.

The data showed that after three courses of MabThera in patients who had an inadequate response to TNF inhibitors:

  • The number of patients achieving the hard-to-reach goal of a 70% improvement in disease signs and symptoms (ACR70 response2) almost tripled from 11% to 25%

  • The number of patients achieving remission improved from 6% to 12%

Equally, in patients with an inadequate response or intolerance to DMARDs, the remission rate increased almost threefold from 5% to 14% confirming the benefit of providing subsequen
'"/>

Contact: Lynn Huynh
lynn_huynh@uk.cohnwolfe.com
44-207-331-5332
Cohn & Wolfe, London
13-Jun-2007


Page: 1 2

Related biology news :

1. Latest strategies for moving research toward a cure for diabetes explored at global scientific forum
2. Latest plant health research to be presented in San Diego
3. Latest advances in DNA sequencing highlighted at DOE Joint Genome Institute User Meeting
4. Latest buzz: Marijuana may slow progression of Alzheimers disease
5. Latest enhancements to the free Access Grid Toolkit are now available for download
6. Slow-frozen people? Latest research supports possibility of cryopreservation
7. Latest plant disease research to be presented in Quebec City
8. Latest study: Scientists say no evidence exists that therapod dinosaurs evolved into birds
9. Latest gene therapy research to be presented in St. Louis, June 1-5, 2005
10. Latest census finds more American pika populations disappear as climate warms
11. Latest buzz in research: Intoxicated honey bees may clue scientists into drunken human behavior

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/29/2017)... , March 29, 2017  higi, the health IT ... North America , today announced a ... the acquisition of EveryMove. The new investment and acquisition ... of tools to transform population health activities through the ... data. higi collects and secures data today ...
(Date:3/27/2017)... ROCKVILLE CENTRE, N.Y. , March 27, 2017 ... by Healthcare Information and Management Systems Society (HIMSS) ... Analytics Outpatient EMR Adoption Model sm . In ... top 12% of U.S. hospitals using an electronic ... recognized CHS for its high level of EMR ...
(Date:3/24/2017)... Research and Markets has announced the addition of the "Global ... to 2025" report to their offering. ... The Global Biometric Vehicle Access System Market ... the next decade to reach approximately $1,580 million by 2025. ... for all the given segments on global as well as regional ...
Breaking Biology News(10 mins):
(Date:7/27/2017)... ... July 27, 2017 , ... ... businesses to participate in Lajollacooks4u’s popular corporate team building events this summer. ... in Lajollacooks4u’s signature olive oil competition to whet their palettes. Three teams ...
(Date:7/26/2017)... ... July 26, 2017 , ... ... worldwide rights to SQuEEZ heart function analysis software, and an associated pending patent ... was filed April 10, 2014 and uses high resolution cardiac CT to analyze ...
(Date:7/26/2017)... Biosciences Inc., a world leading specialty CRO announced the publication ... early stage (latent) Mycobacterium tuberculosis (Mtb) infection using state-of-the-art ProteoCarta™, ... ... Caprion Biosciences Inc. (CNW Group/Caprion Biosciences) ... The new data, recently published in EbioMedicine ...
(Date:7/26/2017)... Ca (PRWEB) , ... July 25, 2017 , ... ... August 22, attendees will garner a better understanding of the considerations needed for ... CRISPR-Cas9 applications. , The use of CRISPR-Cas9 to create targeted double-strand breaks in ...
Breaking Biology Technology:
Cached News: